Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

NICE Announce Nivolumab To Be Available for Some Patients with Head and Neck Cancer

Nivolumab is recommended for use within the Cancer Drugs Fund
27 Oct 2017
Head and neck cancers;  Cancer Immunology and Immunotherapy

NICE announced on 13 October 2017 that the immunotherapy drug, nivolumab (Opdivo, Bristol-Myers Squibb), will be available for patients with head and neck cancer who have not responded to chemotherapy within 6 months, and the cancer has spread to other parts of the body. Nivolumab is recommended for use within the Cancer Drugs Fund (CDF)and hundreds of patients with head and neck cancer will have access to it after new deal.

When NICE first reviewed nivolumab, it was found that the evidence for its effectiveness in treating head and neck cancer was uncertain. NICE invited Bristol-Myers Squibb to submit a CDF proposal to show how they would strengthen the evidence for nivolumab.

Patients can now have access to the drug via the NHS whilst it is within the CDF. During this time, further data will be collected from how well patients do who access the drug through the CDF and from a clinical trial to help address uncertainties in the evidence.

Professor Carole Longson, director of the Centre for Health Technology Evaluation at NICE said: “Nivolumab is an innovative drug that continues to draw attention, but its clinical evidence for some types of cancer can be uncertain. I am pleased the company has worked with us and NHS England to develop a managed access agreement and that we have found a way to provide for patients despite these uncertainties.”

Patients who are being treated with nivolumab must stop at two years of uninterrupted treatment, or earlier if the cancer has spread further around the body. This is because evidence for the effectiveness of nivolumab after two years is uncertain.

There are almost 10,000 cases of newly diagnosed head and neck cancer per year in the UK. An estimated 900 patients are expected to receive nivolumab during the managed access period whilst it is on the CDF for the next two years.

The current clinical trial evidence showed that the drug extends life by more than 3 months compared to current treatments.

The list price for nivolumab is 1,097 GBP per 100 mg vial which is to be administered intravenously in 3mg/kg doses every two weeks per patient. The company has agreed a commercial access agreement with NHS England that provides the drug at a confidential discounted price.

Last update: 27 Oct 2017

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.